CD19 and neoplasm: Chimeric antigen receptor- T (CAR-T) cell therapy uses T-cells, re-engineered to express a designer T-cell receptor (TCR) against a lymphoma directed antigen like CD19 to clinical benefit from tumour cell lysis independent of major histocompatibility (MHC) restricted T-cell receptor activation of T-cells (6).